SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
UnitedHealth Group Incorporated (UNH) trades at a trailing P/E of 23.1, forward P/E of 17.6. Trailing earnings yield is 4.33%, forward earnings yield 5.68%. PEG 0.50 (Peter Lynch undervalued ≤1.0). Graham Number is $182.52.
Criteria proven by this page:
- VALUE (66/100, Pass) — P/E is below market average (23.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.50); analyst target implies upside (+22.7%); earnings yield beats bond yields (4.33%).
- Forward P/E 17.6 (down from trailing 23.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.50 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.33% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.68% as earnings recover.
- Analyst consensus target $385.38 (+22.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
66/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — UNH
Valuation Multiples
P/E (TTM)23.1
Forward P/E17.6
PEG Ratio0.50
Forward PEG0.50
P/B Ratio2.96
P/S Ratio0.62
EV/EBITDA14.4
Per Share Data
EPS (TTM)$13.25
Forward EPS (Est.)$17.85
Book Value / Share$111.76
Revenue / Share$491.83
FCF / Share$17.66
Yields & Fair Value
Earnings Yield4.33%
Forward Earnings Yield5.68%
Dividend Yield2.89%
Graham Number$182.52
SharesGrow IV$902.20 (+187.2%)
Analyst Target$385.38 (+22.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
21.7 |
1.04 |
3.97 |
0.82 |
1.48% |
| 2017 |
20.1 |
0.41 |
4.26 |
1.06 |
1.30% |
| 2018 |
20.0 |
1.46 |
4.64 |
1.06 |
1.38% |
| 2019 |
20.2 |
1.20 |
4.85 |
1.15 |
1.41% |
| 2020 |
21.5 |
1.81 |
5.07 |
1.29 |
1.38% |
| 2021 |
27.4 |
2.18 |
6.60 |
1.65 |
1.12% |
| 2022 |
24.6 |
1.41 |
6.37 |
1.53 |
1.21% |
| 2023 |
21.8 |
1.82 |
5.50 |
1.31 |
1.38% |
| 2024 |
32.6 |
-0.93 |
5.07 |
1.17 |
1.60% |
| 2025 |
24.9 |
-1.62 |
3.19 |
0.67 |
2.64% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.25 |
$184.83B |
$7.24B |
3.9% |
| 2017 |
$10.72 |
$201.16B |
$10.56B |
5.2% |
| 2018 |
$12.19 |
$226.25B |
$11.99B |
5.3% |
| 2019 |
$14.33 |
$242.16B |
$13.84B |
5.7% |
| 2020 |
$16.03 |
$255.64B |
$15.4B |
6% |
| 2021 |
$18.08 |
$285.27B |
$17.29B |
6.1% |
| 2022 |
$21.18 |
$322.13B |
$20.12B |
6.2% |
| 2023 |
$23.86 |
$367.53B |
$22.38B |
6.1% |
| 2024 |
$15.51 |
$400.28B |
$14.41B |
3.6% |
| 2025 |
$13.23 |
$447.57B |
$12.06B |
2.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$17.85 |
$16.68 – $18.11 |
$441.42B |
$439.66B – $444.91B |
20 |
| 2027 |
$19.82 |
$18.18 – $21.45 |
$454.18B |
$443.73B – $483.33B |
19 |
| 2028 |
$23.78 |
$22.00 – $26.31 |
$481.51B |
$480.99B – $482.04B |
10 |
| 2029 |
$28.68 |
$28.08 – $30.10 |
$509.79B |
$501.5B – $529.17B |
4 |
| 2030 |
$32.46 |
$31.77 – $34.06 |
$539.73B |
$530.95B – $560.24B |
4 |
